Contains Waxes, Higher Fatty Acids, Higher Fatty Alcohols Patents (Class 424/502)
  • Patent number: 10543160
    Abstract: The present invention relates to a non-aqueous cosmetic composition comprising water-soluble scrub particles containing a polypeptide or a cell culture component. More specifically, the present invention relates to a non-aqueous cosmetic composition comprising 0.01 wt % to 15 wt % of hard and angulated water-soluble scrub particles containing cell culture components or various polypeptides including a peptide and an oligopeptide. Further, the cosmetic composition of the present invention provides a non-aqueous cosmetic composition which does not comprise active ingredients, but comprises water-soluble excipient scrub particles for maintaining or improving a scrubbing effect and adjusting viscosity or volume.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: January 28, 2020
    Assignee: Paean Aesthetics Inc.
    Inventors: Kyuboem Han, Seong Soo Jeon, Jongcheon Ha
  • Patent number: 9675820
    Abstract: Methods and systems for passively detecting stable cavitation and enhancing stable cavitation during sonothrombolysis are provided. The method of passively detecting stable cavitation includes providing a determined level of ultrasonic energy and detecting a scattered level of ultrasonic energy. The system for inducing and passively detecting stable cavitation includes a dual-element annular transducer array configured to provide a fundamental ultrasonic frequency and to detect an ultrasonic frequency that is a derivative of the fundamental frequency. The method of enhancing stable cavitation includes administering a nucleating agent and a thrombolytic agent to a treatment zone, providing a determined level of ultrasonic energy, and detecting a scattered level of ultrasonic energy.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: June 13, 2017
    Assignee: University of Cincinnati
    Inventors: Christy K. Holland, Saurabh Datta, T. Douglas Mast, Nikolas Ivancevich, Kathryn Elizabeth Hitchcock, Kevin Haworth
  • Patent number: 9622949
    Abstract: A formulation for personal hygiene in the form of O/W emulsion with a pH from 5.5 to 6.5, free of surfactants, comprising an emulsifier consisting of a fatty alcohol from 14 to 22 carbon atoms or of Glyceryl Stearate or a mixture thereof, Coco Caprylate and/or Coco Caprylate/Caprate, vitamin E or an ester thereof, and Melaleuca alternifolia oil.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: April 18, 2017
    Assignee: BIO.LO.GA. S.R.L
    Inventor: Giorgio Panin
  • Patent number: 9326949
    Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: May 3, 2016
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Michele Boix, Christian Sarrazin, Marina Do
  • Patent number: 9320588
    Abstract: A method for treating fecal incontinence in a body of a mammal having a rectum formed by a rectal wall extending to an anus wherein the rectal wall includes a sphincter muscle surrounding the anus. At least one nonaqueous solution is introduced into the rectal wall in the vicinity of the anus. A nonbiodegradable solid is formed in the rectal wall from the at least one nonaqueous solution.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: April 26, 2016
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: David E. Silverman, Alan J. Stein
  • Patent number: 9260471
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: February 16, 2016
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Mark Cancilla, James J. Cunningham, Michael W. Flanagan, Henry J. Haringsma, Denise Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron Willingham
  • Publication number: 20150132400
    Abstract: The present invention relates to a granulate comprising granules made up of 40-99 wt. % of lactose particles and 1-60 wt. % of a binding component that holds together the lactose particles within the granules. Said granules have a mass weighted average diameter of 50-500 ?m and said binding component is a solid dispersion or a solid solution of 10-75 wt. % of a cannabinoid in 25-80 wt. % of a lipophilic matrix. The lipophilic matrix contains at least 80 wt. % sucrose fatty acid mono-ester, the fatty acid residue being selected from C8-C18 fatty acids. The aforementioned granulate can be processed into oral dosage units in the form of tablets for oral delivery. The invention further provides a method for the manufacture of the granulate.
    Type: Application
    Filed: May 3, 2013
    Publication date: May 14, 2015
    Applicant: Echo Pharmaceuticals B.V.
    Inventors: Jan Albert De Vries, Maria Vanesa Fernandez Cid, Ana Maria Heredia Lopez
  • Patent number: 9017812
    Abstract: A process of producing polylactic acid-based resin microparticles includes a dissolving process that forms a system, which can cause phase separation into two phases of a solution phase mainly composed of polylactic acid-based resin (A) and a solution phase mainly composed of polymer (B) different from polylactic acid-based resin, by dissolving the polylactic acid-based resin (A) and the polymer (B) different from polylactic acid-based resin in an ether-based organic solvent (C), an emulsion-forming process that forms an emulsion by applying a shear force to the system, and a microparticle-forming process that precipitates polylactic acid-based resin microparticles by contacting the emulsion with a poor solvent which has lower solubility of the polylactic acid-based resin (A) than the ether-based organic solvent (C).
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: April 28, 2015
    Assignee: Toray Industries, Inc.
    Inventors: Hiroshi Takezaki, Hiroshi Kobayashi, Makiko Saito, Itaru Asano
  • Patent number: 8999397
    Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: April 7, 2015
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Michele Boix, Christian Sarrazin, Marina Do
  • Patent number: 8999686
    Abstract: Methods and compositions, including nucleotide sequences, amino acid sequences, and host cells, for producing fatty alcohols are described.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: April 7, 2015
    Assignee: REG Life Sciences, LLC
    Inventors: Zhihao Hu, Vikranth Arlagadda
  • Patent number: 8992994
    Abstract: The present invention relates to stable topical pharmaceutical compositions for the treatment of psoriasis. Disclosed are in particular nonoemulsions comprising nano size droplets of one or more anti-psoriasis agents, e.g. clobetasol and/or salicylic acid. These compositions exhibit greater permeability, and improved bioavailability. The invention also relates to processes for the preparation of such compositions.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: March 31, 2015
    Assignee: Cadila Healthcare Limited
    Inventors: Sunilendu Bhushan Roy, Jay Shantilal Kothari, Shafiq Sheikh, Jitendra Dasharathlal Patel, Jinesh Suresh Pancholi
  • Publication number: 20150086643
    Abstract: A traditional Chinese medicine compound antitumor nano preparation, comprising the following components by weight percentage: 28%-32% of solid lipid nanoparticles containing volatile oil of frankincense and myrrh, 61%-65% of nano realgar carrying microcapsule, 0.8%-1.3% of bezoar micro-powder and 4%-6% of musk micro-powder. Use of the above traditional Chinese medicine compound antitumor nano preparation for preparing antitumor drugs. The traditional Chinese medicine compound antitumor nano preparation of the present invention can remarkably improve bioavailability of every component in the traditional Chinese medicine compound; at the same time, it can achieve better curative effect with reduced dosage.
    Type: Application
    Filed: February 13, 2014
    Publication date: March 26, 2015
    Inventors: Nianping Feng, Feng Shi, Ying Liu, Jihui Zhao, Yongtai Zhang
  • Patent number: 8986720
    Abstract: Disclosed is a topical skin care composition and corresponding methods for its use comprising water, a cationic surfactant, an occlusive skin conditioning agent, a humectant skin conditioning agent, and a silicone containing compound. The composition is dermatologically acceptable and is capable of moisturizing skin for at least twelve hours after topical application to skin even after multiple washings of the skin.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: March 24, 2015
    Assignee: Mary Kay Inc.
    Inventor: Bob Walke
  • Patent number: 8986737
    Abstract: A method of treating or preventing infection at a surgical site comprising a bony defect and an implanted metal device is disclosed. Biodegradable microspheres are placed at the site and are capable of near-linear controlled release of an antibiotic agent for a predetermined period of time. The microspheres are configured to be large enough to avoid being phagocytosed and removed from the body, and small enough in diameter to not physically inhibit bone growth at said bony defect site. The microspheres are formed of polylactic-co-glycolic acid (PLGA), with or without polyethylene glycol (PEG), and sufficient antibiotic agent to produce bactericidal levels in body tissues. The microspheres exhibit near-linear delivery of the antibiotic agent for at least 4 weeks at levels exceeding the minimum inhibitory concentration (MIC) for organisms commonly found to be the cause of infections, and facilitate bone ingrowth or regrowth at the site.
    Type: Grant
    Filed: December 10, 2008
    Date of Patent: March 24, 2015
    Assignees: Wm. Marsh Rice University, Board of Regents of the Univeristy of Texas System
    Inventors: Catherine G. Ambrose, Terry A. Clyburn, Antonio G. Mikos
  • Publication number: 20150044297
    Abstract: The invention relates to a novel galenical system for taste masking, protecting an active substance, in particular in an acid medium, modulating releasing properties, masking mucous irritability and toxicity of certain active substances, for preparing aqueous forms which have a masked taste, are stable and pH independent. Said invention also relates, in particular to a galenical system which is embodied in the form of lipidic solid particles and strictly hydrophobic and devoid of water, surface active agents, emulsifiers, solvent traces and which is characterized in that it comprises at least one type of hydrophobic wax and at least one type of fatty non-neutralised acid.
    Type: Application
    Filed: October 27, 2014
    Publication date: February 12, 2015
    Inventors: Karim Ioualalen, Rose-Anne Raynal
  • Publication number: 20150004244
    Abstract: Tamper-resistance pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.
    Type: Application
    Filed: June 30, 2014
    Publication date: January 1, 2015
    Inventors: Roman RARIY, Alison Fleming, Jane C. Hirsh, Said SAIM, Ravi K. Varanasi
  • Patent number: 8916214
    Abstract: A process is described for obtaining free flowable, carrier free powders from aqueous solutions of deliquescent quaternary ammonium compounds in a two step process, comprising a drying and a powder mixing step. The excellent free-flowing and stability characteristics of the final product could only be obtained when among possible other additives at least one univalent metal fatty acid salt is added to the liquid phase in the drying step and at least one multivalent metal fatty acid salt in the powder mixing step. A surprising synergy was observed between these additives when applied as described in the present invention.
    Type: Grant
    Filed: December 24, 2009
    Date of Patent: December 23, 2014
    Assignee: Taminco N.V.
    Inventors: Kristof Moonen, Daan Scheldeman
  • Patent number: 8911788
    Abstract: The invention relates to a novel galenical system for taste masking, protecting an active substance, in particular in an acid medium, modulating releasing properties, masking mucous irritability and toxicity of certain active substances, for preparing aqueous forms which have a masked taste, are stable and pH independent. Said invention also relates, in particular to a galenical system which is embodied in the form of lipidic solid particles and strictly hydrophobic and devoid of water, surface active agents, emulsifiers, solvent traces and which is characterized in that it comprises at least one type of hydrophobic wax and at least one type of fatty non-neutralized acid.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: December 16, 2014
    Assignee: Capsugel France SAS
    Inventors: Karim Ioualalen, Rose-Anne Raynal
  • Patent number: 8906416
    Abstract: The invention relates to compound of generic formula (I) in which: R1 and R2 represent: OH, a hydrogen atom, a C1-C6 alkyl radical a C1-C6 alkoxy radical, a halogen, or OCOR3; R3 represents: a C1-C24 alkyl radical a C12-C24 alkenyl radical comprising at least one unsaturation; R4 represents: COR5, a glucide substituted or not by one or more acetyl radical(s); R5 represents: a C10-C24 alkyl radical or a C12-C24 alkenyl radical comprising at least one unsaturation; R6 and R7 represent:—simultaneously a hydrogen atom or a methyl radical, or—when R6 represents a hydrogen atom, R7 represents a C1-C6 alkyl radical or a phenyl substituted or not by one or more C1-C3 alkoxy radical(s) or one or more halogen(s) or—R6 and R7 are bonded together and form a C3-C6 cycloalkyl, and pharmaceutically or cosmetically acceptable salts.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: December 9, 2014
    Assignee: Pierre Fabre Dermo-Cosmetique
    Inventors: Stéphane Poigny, Françoise Belaubre
  • Publication number: 20140348938
    Abstract: The present invention relates to a simple and convenient process for preparing solid lipid sustained release nanoparticles for delivery of drugs/vitamins, preferably fat soluble vitamins and more specifically Vitamin D3 and retinoic acid (RA). The process involves microemulsion technique. The nanoparticles of Vitamin D3 and RA obtained by the process of the present invention have utility in treatment of diseases like tuberculosis. Use may be extended to other diseases like AMD, diabetic retinopathy, cancers, hyperpigmentation, acne, and osteoporosis.
    Type: Application
    Filed: January 9, 2013
    Publication date: November 27, 2014
    Inventors: Indu Pal Kaur, Manoj Kumar Verma
  • Publication number: 20140349850
    Abstract: The present invention relates to coated dehydrated microorganisms comprising a dehydrated microorganism surrounded by at least one coating, said coating comprising by dry weight at least 25% of hygroscopic salt(s) and wherein the pH of the coating is compatible with viability of the coated dehydrated microorganism. The coating can be partially crystalline, the salt(s) in the coating having preferably a crystallinity degree of up to 60% once applied onto the dehydrated microorganism. The present invention also relates to liquid coating compositions, methods for coating and protecting a dehydrated microorganism. Finally, the present invention relates to a method for the preparation of food products, feed products, consumer healthcare products or agri-products as well as to a food product, feed product, a consumer healthcare product or an agri-product containing such coated dehydrated microorganisms.
    Type: Application
    Filed: August 13, 2014
    Publication date: November 27, 2014
    Inventors: Isabelle Mazeaud, Kathryn Tse, Jean-Philippe Obert, Claudette Berger, Geoffrey Babin, Patrick Chaigneau, Hans Hedegaard Jensen, Erwan Henri
  • Patent number: 8889189
    Abstract: There are described solid compositions or examining drug solubility comprising bile salts and phospholipids, optionally containing buffer components suitable for preparation of intestinal media that simulate the composition of the intestinal fluids in fasted and fed states.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: November 18, 2014
    Assignee: Phares Pharmaceutical Research, N.V.
    Inventors: Steve Leigh, Mathew Louis Steven Leigh, Peter Van Hoogevest, Daniel Streich, Jacques Quinton
  • Patent number: 8883220
    Abstract: The disclosure describes nanocarried and/or microcarried jasmonate compounds and their pharmaceutical compositions, as well as use thereof for treating or preventing angiogenesis-related or NF-?B-related disorders. Also disclosed are methods of making the nanocarried and/or microcarried compounds and their compositions.
    Type: Grant
    Filed: September 17, 2012
    Date of Patent: November 11, 2014
    Assignee: NanoCare Technologies, Inc.
    Inventor: José E. Fehr Pereira Lopes
  • Patent number: 8882902
    Abstract: The present invention relates to a composite pigment comprising a substrate, said substrate being at least in part covered by at least one layer comprising at least one solid organic UV filter. The composite pigment can be prepared by a method comprising a step of subjecting a substrate, at least one solid organic UV filter, and optionally at least one solid inorganic UV filter, at least one additional UV filter and/or at least one coloring pigment, to a mechanochemical fusion process such as a hybridizer process. The composite pigment can be advantageously used as a component for a cosmetic composition.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: November 11, 2014
    Assignee: L'Oreal
    Inventors: Takahiro Suzuki, Takehiko Kasai
  • Patent number: 8877242
    Abstract: The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
    Type: Grant
    Filed: July 14, 2009
    Date of Patent: November 4, 2014
    Assignee: Polypid Ltd.
    Inventors: Noam Emanuel, Moshe Neuman, Shlomo Barak
  • Patent number: 8858917
    Abstract: Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as vital infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be a surfactant and, optionally, a carrier. The formulation may be administered as a powder where the particles consist basically of the material altering surface tension. The carrier may be a solution, such as an alcohol, although an aqueous solution may be utilized, or a material mixed with the material altering surface tension to form particles.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: October 14, 2014
    Assignee: President and Fellows of Harvard College
    Inventors: David A. Edwards, Howard A. Stone
  • Patent number: 8859487
    Abstract: A perfume tester or perfume includes a granule containing a friable peripheral portion incorporating fragrant compounds, which disintegrates as a perfumed powder when the granule is applied onto the skin. A method for making the perfume tester or perfume is by granulation, and the granule can be used in particular for perfume testing.
    Type: Grant
    Filed: July 30, 2007
    Date of Patent: October 14, 2014
    Assignee: Laboratoires Docteur Gaetano Zannini
    Inventors: Jean-Pierre Mathonnet, Gaetano Zannini
  • Patent number: 8840928
    Abstract: Tamper-resistant pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: September 23, 2014
    Assignee: Collegium Pharmaceutical, Inc.
    Inventors: Roman V. Rariy, Alison B. Fleming, Jane C. Hirsh, Said Saim, Ravi K. Varanasi
  • Publication number: 20140271899
    Abstract: The present invention provides methods and liposomal compositions useful in therapeutics, and diagnosis, prognosis, testing, screening, treatment and/or prevention of various disease conditions. The present invention provides imaging methods for various conditions. The present invention is a multi-layered drug delivery pathway, inclusive of nanoparticle liposomal formulations and mechanisms of localized action via unzipping upon delivery to the affected tissue site. The nano-encapsulation methodology allows maximization of a potent antioxidant's biocompatibility, increased target cell penetration and uptake, reduced off-target effects and retention of high anti-oxidative activity for promising therapeutic potential.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: PEROXYIUM, INC., DELAWARE C CORP.
    Inventors: James Leiter, Susan Gillmor, Aleksandar Jeremic, Ekaterina Vert-Wong, Gregg Fairbrothers
  • Patent number: 8828446
    Abstract: Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: September 9, 2014
    Assignee: Allergan, Inc.
    Inventor: Vernon G. Wong
  • Publication number: 20140212504
    Abstract: Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.
    Type: Application
    Filed: April 2, 2014
    Publication date: July 31, 2014
    Inventors: Jeffry G. WEERS, Thomas E. TARARA, Luis A. DELLAMARY, Jean G. RIESS, Ernest G. SCHUTT
  • Publication number: 20140199407
    Abstract: The described invention provides organometallic complexes capable of spin transfer, comprising at least three different metals and the use of pharmaceutical compositions comprising such complexes in detoxification of reactive oxygen species in inflammatory conditions.
    Type: Application
    Filed: March 11, 2013
    Publication date: July 17, 2014
    Inventor: Merrill Garnett
  • Patent number: 8779000
    Abstract: Embodiments of the present invention provide pharmaceutical compositions in unit dosage form that comprise a therapeutically effective amount of levothyroxine sodium; an antioxidant in an amount sufficient to stabilize the levothyroxine sodium against oxidation; an amount of an alditol sufficient to stabilize the levothyroxine sodium; and at least two excipients selected from a filler, a binder, and a lubricant. Such compositions are free of added monosaccharide, disaccharide, and an oligosaccharide and are storage stable.
    Type: Grant
    Filed: July 20, 2013
    Date of Patent: July 15, 2014
    Inventors: Nilesh Parikh, William Hite
  • Patent number: 8771747
    Abstract: Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(?-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: July 8, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Derek O'Hagan, Gary S. Ott, John Donnelly, Jina Kazzaz, Mildred Ugozzoli, Manmohan Singh, John Barackman
  • Patent number: 8758820
    Abstract: Compositions and methods for making robust pellets that contain a high percentage, by weight, of active drug agent, and which also contain additional components that enhance the absorption and solubility of the active drug agent within the gastrointestinal tract (GI tract) without diminishing the robust nature of the pellet, are disclosed.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: June 24, 2014
    Assignee: Shionogi Inc.
    Inventors: Bruce X. Cao, Beth A. Burnside, Sandra E. Wassink, Matt R. Baker
  • Patent number: 8741321
    Abstract: A capsule for cosmetic and/or dermatological ingredients and processes for the production thereof. The capsule comprises an envelope which is solid, semisolid and/or dimensionally stable and comprises one or more substances which are selected from waxes, emulsifiers, and natural and synthetic polymers. The capsule may also comprise a filling.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: June 3, 2014
    Assignee: Beiersdorf AG
    Inventors: Volker Kallmayer, Jens Nielsen, Andreas Bleckmann, Heidi Riedel, Julia Eckert, Thomas Raschke, Frank Teuber, Corinna Zu Putlitz, Stephanie Conzelmann, Kathrin Liste, Uta Kruse, Yvonne Eckharol
  • Patent number: 8734832
    Abstract: Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(?-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided.
    Type: Grant
    Filed: September 15, 2012
    Date of Patent: May 27, 2014
    Assignee: Novartis AG
    Inventors: Derek O'Hagan, Gary S. Ott, John Donnelly, Jina Kazzaz, Mildred Ugozzoli, Manmohan Singh, John Barackman
  • Patent number: 8722093
    Abstract: The present invention provides nanoparticulate policosanol, formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: May 13, 2014
    Assignee: NanoRx, Inc.
    Inventor: Palayakotai R. Raghavan
  • Patent number: 8709484
    Abstract: Phospholipid based powders for drug delivery applications are disclosed. The powders may include a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: April 29, 2014
    Assignee: Novartis AG
    Inventors: Jeffry G. Weers, Thomas E. Tarara, Luis A. Dellamary, Jean G. Riess, Ernest G. Schutt
  • Patent number: 8709379
    Abstract: Formulations of neutral retinoids, in particular fenretinide (HPR) in the form of lipid nanoparticles, solid dispersions and emulsions are disclosed. These compositions are used to treat diseases that are amenable to treatment by HPR, such as neoplastic diseases by achieving higher and more prolonged concentrations of HPR in the subject. The key steps for preparing lipid nanovesicles of HPR include mixing and sonication, sterile filtration, without or without lyophilization for long-term stable storage, and employ processes and materials that are scalable from the laboratory to the manufacturing level. The formulation are suitable for injection into human or animal patients without causing allergic or hypersensitivity responses by avoiding chemical surfactants and animal sources of phospholipids in their manufacture.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: April 29, 2014
    Assignee: Scitech Development, LLC
    Inventors: Ralph E. Parchment, Bhaskara R. Jasti, Ramesh R. Boinpally, Stephen E. Rose, Earle T. Holsapple
  • Patent number: 8703189
    Abstract: The present invention provides a medicinal composition that exhibits excellent storage stability and, even over long-term storage, little change in the release rate of the pharmacologically active substance contained therein. The medicinal composition of the invention prepared by dissolving or dispersing a pharmacologically active substance and a pH-independent water-insoluble polymer in a molten low-melting substance, and which can be prepared by spraying a liquid substance, obtained by dissolving or dispersing the pharmacologically active substance in a molten mixture comprising the low-melting substance and the pH-independent water-insoluble polymer, and then cooling the liquid substance.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: April 22, 2014
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Yuso Tomohira
  • Publication number: 20140105963
    Abstract: The present invention generally relates to compositions and methods for transdermal drug delivery. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction, treating wounds, or causing or promoting hair growth. For example, in one aspect, the present invention is generally directed to compositions for delivery of nitric oxide, transdermally and/or to a mucosal surface. The composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. In some embodiments, a composition comprising nitric oxide is unexpectedly stable and can be stored long-term.
    Type: Application
    Filed: December 6, 2013
    Publication date: April 17, 2014
    Applicant: Transdermal Biotechnology, Inc.
    Inventors: Nicholas V. Perricone, Yousry Abdelrehim Sayed
  • Patent number: 8685425
    Abstract: Microcapsules possessing Lewis acid-Lewis base salt walls incorporate water-immiscible materials, such as N,N-di-ethyl-m-toluamide (DEET), as a core component. Such microcapsules, or similar microcapsules incorporating other core components, may be made by emulsifying a water-immiscible core component in an aqueous solution of one wall-forming reactant, such as the Lewis base, and then mixing that solution with the other wall-forming reactant, such as the Lewis acid. Various adjuvants may be included with the core component to contribute additional characteristics, such as enhancement of a controlled release characteristic or improved mechanical stability.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: April 1, 2014
    Inventor: Tycho J. Speaker
  • Patent number: 8679546
    Abstract: The subject of this invention is a controlled release composition for zootechnical use. In particular, the subject of this invention is a composition comprising micro-pellets that are able to release the physiologically active substances they contain in a controlled manner. In addition, this invention refers to a procedure for preparing said composition as well as the use of said composition in the zootechnical sector.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: March 25, 2014
    Assignee: Valentini S.R.L.
    Inventors: Paolo Cavassini, Paolo Cicognani, Jean Antoine Meiners
  • Publication number: 20140079796
    Abstract: Low melting propionic acid derivative particles that are free flowing and have significantly reduced or eliminated throat burn are disclosed. A method of manufacturing the low melting propionic acid derivative particles; dosage forms containing the low melting propionic acid derivative particles; methods of manufacturing the dosage forms; and methods of treatment using the dosage forms are also disclosed.
    Type: Application
    Filed: September 16, 2013
    Publication date: March 20, 2014
    Applicant: McNeil-PPC, Inc.
    Inventors: Saumitra Bagchi, Murali K. Vuppala
  • Patent number: 8658193
    Abstract: Technologies are described herein for styptic compounds comprising a hemostatic or styptic agent suspended within a hydrophobic carrier medium. Example carrier mediums may include waxes, lipids, oils, or combinations thereof. The compound may be a semisolid at room temperature and soft enough to be easily dispensed and formed into or onto bleeding tissue of an animal or human. The hydrophobic qualities of the carrier medium can protect the styptic agent from absorbing moisture. The carrier medium can mechanically support positioning treatments adjacent to the bleeding tissue. The carrier medium can further serve to mechanically seal the tissue to aid in hemostasis while also protecting the tissue from debris and contamination. The carrier medium can aid in maintaining moisture within the tissue. Slurry-based manufacturing processes can support a substantially homogeneous dispersal of styptic agent throughout the carrier medium.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: February 25, 2014
    Inventor: Robert J. Greenwald
  • Patent number: 8647647
    Abstract: A topical formulation for application to exposed body tissue, the formulation comprising a silver(II) oxide and zinc oxide, intimately dispersed within a carrier medium.
    Type: Grant
    Filed: July 21, 2010
    Date of Patent: February 11, 2014
    Assignee: Aidance Skincare and Topical Solutions, LLC
    Inventor: Perry Antelman
  • Publication number: 20140030352
    Abstract: The present invention provides a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a water miscible solvent and water, said nanoparticles comprising one or more taxane derivative, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol or its derivatives or its salts.
    Type: Application
    Filed: October 3, 2013
    Publication date: January 30, 2014
    Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Ajay Jaysingh KHOPADE, Subhas Balaram BHOWMICK, Natarajan ARULSUDAR
  • Publication number: 20140023718
    Abstract: There is provided a fat emulsion which has a pH of 4.5 to 6.0 and includes a prostaglandin compound, an oil ingredient, a lecithin, the content of which is 0.15 times or more by mass the content of the oil ingredient, a water-soluble acid having a pKa of 4.0 to 6.0 and having a dissociable group or a salt thereof, and water; and a fat emulsion which includes a prostaglandin compound, an oil ingredient, a lecithin, the content of which is 500 to 5,000 times by mass the content of the prostaglandin compound and is 0.5 to 10 times by mass the content of the oil ingredient, and water, and in which the content of a higher fatty acid is 0.06 times or less by mass the content of the lecithin.
    Type: Application
    Filed: September 27, 2013
    Publication date: January 23, 2014
    Applicant: FUJIFILM Corporation
    Inventors: Shigetomo TSUJIHATA, Hiroki TANISAKA, Kozo NAGATA, Yasuyuki IZUMI
  • Publication number: 20140017329
    Abstract: A composition and an associated method for hepatic targeted delivery of thyroid receptor beta1 (TR?1) agonist to a liver of a subject. The composition includes hydrophobic nanoparticles, a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, and at least one TR?1 agonist encapsulated within each nanoparticle. The nanoparticles include chitosan hybrid nanoparticles, amine-modified PLGA nanoparticles, solid lipid nanoparticles, and combinations thereof. The liver targeting moiety includes Glycyrrhetinic acid (GA), Lactobionic acid (LA), or combinations thereof.
    Type: Application
    Filed: July 10, 2013
    Publication date: January 16, 2014
    Inventor: Shaker A. Mousa